{
    "clinical_study": {
        "@rank": "60468", 
        "arm_group": [
            {
                "arm_group_label": "Oprozomib with Pomalidomide and Dexamethasone (OPomd)", 
                "arm_group_type": "Experimental", 
                "description": "Phase 1b:\nOprozomib doses will be escalated in sequential groups of at least 3 subjects. Study subjects will receive oprozomib in combination with pomalidomide and dexamethasone. Assuming no dose de-escalation is needed, pomalidomide and dexamethasone doses will remain fixed, while the dose of oprozomib for subsequent cohorts will be escalated until the MTD is reached.\nPhase 3:\nStudy subjects will receive oprozomib in combination with pomalidomide and dexamethasone."
            }, 
            {
                "arm_group_label": "Placebo with Pomalidomide and Dexamethasone (Pomd)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Phase 3:\nStudy subjects will receive placebo in combination with pomalidomide and dexamethasone."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of Phase 1 of the study is to determine the maximum tolerated dose and assess\n      the safety, tolerability and activity of oprozomib in combination with pomalidomide and\n      dexamethasone in subjects with primary refractory or relapsed and refractory multiple\n      myeloma.\n\n      The purpose of Phase 3 of the study is to compare the key outcome measures for subjects with\n      primary refractory or relapsed and refractory multiple myeloma who are randomized to either\n      oprozomib or placebo in combination with pomalidomide and dexamethasone."
        }, 
        "brief_title": "A Study of Oprozomib, Pomalidomide, and Dexamethasone in Subjects With Primary Refractory or Relapsed and Refractory Multiple Myeloma", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Multiple myeloma that is primary refractory or relapsed and refractory after at least\n             2 lines of standard for multiple myeloma including:\n\n             a. > 2 consecutive cycles of both bortezomib and lenalidomide or thalidomide (alone\n             or in combination) i. Patients who received bortezomib as their last therapy who were\n             not refractory but developed bortezomib intolerance, as defined by the development of\n             Grade 2 peripheral neuropathy with pain or > Grade 3 peripheral neuropathy after \u2265 2\n             consecutive cycles, are eligible\n\n             b. Adequate alkylator therapy defined as: i. High-dose melphalan or other alkylating\n             agent as conditioning for autologous or allogeneic stem cell transplant (SCT), or ii.\n             \u2265 6 cycles of induction therapy, or iii. PD after \u2265 2 cycles\n\n          2. Disease progression on or within 60 days of completion of the last therapy\n\n          3. Measurable disease as indicated by 1 or more of the following:\n\n               1. Serum M-protein \u2265 500 mg/dL\n\n               2. Urine M-protein \u2265 200 mg/24 h\n\n               3. For patients without measurable serum or urine M protein, serum free light chain\n                  (SFLC): Involved free light chain (FLC) concentration \u2265 10 mg/dL provided SFLC\n                  ratio is abnormal\n\n          4. Males and females \u2265 18 years old\n\n          5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n\n        Key Exclusion Criteria:\n\n          1. Systemic chemotherapy with approved or investigational anticancer therapeutics,\n             including steroid therapy intended to treat underlying malignancy, within 3 weeks\n             before the first dose or 6 weeks for antibody therapy\n\n          2. Dexamethasone at cumulative doses greater than 160 mg or equivalent within 14 days\n             prior to the first dose of study treatment is not allowed. Use of topical or inhaled\n             steroids is acceptable.\n\n          3. Radiation therapy within 3 weeks before first dose. Radioimmunotherapy within 8 weeks\n             before first dose.\n\n          4. Autologous SCT within 8 weeks and allogeneic SCT within 16 weeks prior to initiation\n             of study treatment. Patients with prior allogeneic SCT should not have evidence of\n             moderate-to-severe graft-versus-host disease (as defined in Filipovich 2005).\n\n          5. Known hypersensitivity to any immunomodulatory drugs (IMiDs), including Grade 4 rash\n\n          6. Prior treatment of any duration with pomalidomide\n\n          7. Known hypersensitivity or intolerance to dexamethasone\n\n          8. Prior exposure to oprozomib\n\n          9. Congestive heart failure (New York Heart Association Class III to IV), symptomatic\n             ischemia, conduction abnormalities uncontrolled by conventional intervention, or\n             myocardial infarction within 6 months before first dose"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "314", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999335", 
            "org_study_id": "OPZ007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Oprozomib with Pomalidomide and Dexamethasone (OPomd)", 
                "description": "Study subjects will receive oprozomib tablets once daily on Days 1-5 and 15-19 (QD \u00d7 5 bimonthly schedule) of each 28-day treatment cycle.", 
                "intervention_name": "Oprozomib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Oprozomib with Pomalidomide and Dexamethasone (OPomd)", 
                    "Placebo with Pomalidomide and Dexamethasone (Pomd)"
                ], 
                "description": "Study subjects will receive pomalidomide once-daily on Days 1-21 of every 28-day cycle.", 
                "intervention_name": "Pomalidomide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Oprozomib with Pomalidomide and Dexamethasone (OPomd)", 
                    "Placebo with Pomalidomide and Dexamethasone (Pomd)"
                ], 
                "description": "Study subjects will receive dexamethasone once daily on days 1-2, 8-9, 15-16, and 22-23 of every 28-day cycle.", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Thalidomide", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "West Hollywood", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "James R. Berenson, MD, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado"
                    }, 
                    "name": "Rocky Mountain Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Cornell University"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Levine Cancer Institute"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "University of Pennsylvania"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects", 
        "overall_contact": {
            "email": "medinfo@onyx.com", 
            "last_name": "Onyx Medical Information", 
            "phone": "1-877-669-9121"
        }, 
        "overall_official": {
            "affiliation": "Onyx Therapeutics, Inc.", 
            "last_name": "Linda Neuman, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Greece: Ministry of Health and Welfare", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To compare progression-free survival (PFS), as determined by Onyx Response Computational Assessment (ORCA) according to the IMWG-URC, between subjects treated with oprozomib in combination with pomalidomide and dexamethasone (OPomd) and those treated with pomalidomide and dexamethasone (Pomd)", 
                "measure": "Progression-free Survival (PFS) - Phase 3", 
                "safety_issue": "No", 
                "time_frame": "Approximately 14 months"
            }, 
            {
                "description": "To determine the maximum tolerated dose (MTD) and identify the recommended Phase 3 dose (RP3) of oprozomib in combination with pomalidomide and dexamethasone (OPomd) in subjects with primary refractory or relapsed and refractory multiple myeloma", 
                "measure": "Maximum Tolerated Dose (MTD) - Phase 1b", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 6 months"
            }, 
            {
                "description": "Number of patients that experience Adverse Events (AEs)", 
                "measure": "Adverse Events (AEs) - Phase 1b & Phase 3", 
                "safety_issue": "Yes", 
                "time_frame": "Until 30 days after the end of study (32 months)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999335"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall Survival (OS) is defined as time from randomization to death due to any cause.", 
                "measure": "Overall Survival (OS) - Phase 3", 
                "safety_issue": "No", 
                "time_frame": "14 months"
            }, 
            {
                "description": "To estimate the overall response rate (ORR) of oprozomib in combination with pomalidomide and dexamethasone (OPomd), defined as the proportion of subjects with a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as determined by investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC)", 
                "measure": "Overall Response Rate (ORR) - Phase 1b & Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }, 
            {
                "description": "To estimate the clinical benefit rate (CBR) of oprozomib in combination with pomalidomide and dexamethasone (OPomd), defined as the proportion of subjects with best overall response of minimal response (MR) or better as determined by investigator according to the International Myeloma Working Group Uniform Response Criteria (IMWG-URC) and modified European Group for Blood and Marrow Transplantation (EBMT) criteria", 
                "measure": "Clinical Benefit Rate (CBR) - Phase 1b & Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }, 
            {
                "description": "Duration of Response (DOR) is defined as the time from the first evidence of confirmed partial response (PR) or better to disease progression or death due to any cause as determined by ORCA according to the IMWG-URC and modified EBMT criteria.", 
                "measure": "Duration of Response (DOR) - Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }, 
            {
                "description": "Changes in health-related quality of life (HRQOL) using the EORTC QLQ-C30 Global Health Status/QOL scale", 
                "measure": "Health-Related Quality of Life (HRQOL) - Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }, 
            {
                "description": "Measures of bone pain using the brief pain index (BPI), EORTC QLQ-MY20, and selected subscales of the EORTC QLQ-C30", 
                "measure": "Bone Pain - Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }, 
            {
                "description": "Improvement in renal function over time, as defined by an increase in glomerular filtration rate (GFR) of at least 10 mL/min", 
                "measure": "Improvement in Renal Function - Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }, 
            {
                "description": "Improvement in hemoglobin over time, as defined by an increase of \u2265 2 g/dL", 
                "measure": "Improvement in Hemoglobin - Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }, 
            {
                "description": "Maximum plasma concentration (Cmax)", 
                "measure": "Maximum Plasma Concentration (Cmax) - Phase 1b & Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }, 
            {
                "description": "Time of Maximum Plasma Concentration (Tmax)", 
                "measure": "Time of Maximum Plasma Concentration (Tmax) - Phase 1b & Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }, 
            {
                "description": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and to infinity (AUC0-last and AUC0-\u221e)", 
                "measure": "Total Plasma Exposure (AUC) - Phase 1b & Phase 3", 
                "safety_issue": "No", 
                "time_frame": "31 months"
            }
        ], 
        "source": "Onyx Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Onyx Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}